Moderna’s Sales Miss Forecasts by 20%. Pfizer Is Taking the U.S. Vaccine Market.

3 years ago 448

Moderna shares plunged 12.3% successful premarket trading connected Thursday aft income of the company’s Covid-19 vaccine fell abbreviated of Wall Street analysts’ estimates by much than a cardinal dollars.

The institution reported full gross of $5 cardinal for the 3rd 4th of the year, 20% abbreviated of the FactSet expert statement estimation of $6.2 billion. Spikevax, Moderna‘s (ticker: MRNA) Covid-19 vaccine, is the company’s lone product.

The...

Read Entire Article

Moderna’s Sales Miss Forecasts by 20%. Pfizer Is Taking the U.S. Vaccine Market.

Related

How To Stay Ahead of the Competition with Expert Guest Posts...

Mohamed El-Erian says ‘trifecta’ of dangers will haunt the U...

Adobe Stock Sinks as Fiscal 2022 Forecast Falls Short of Est...

Boeing Loses Qantas Business to Airbus. But There’s Good New...

Trending

Popular

WATCH: Neal Katyal Says That if Weisselberg Doesn’t Cooperat...

Akamai adds new capabilities and tools for developers

What We Learned About Amazon's Warehouse Workers

NY Got Close to Passing Single-Payer Healthcare–Then Special...

Biden to Nominate 5 More Judges